GlassScriptPhysician profile
Anna L Harp
NPI 1124552443
$11,846.03
in general payments reported to CMS, 2019-2025
23 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,447 · 2022: $2,129 · 2023: $3,726 · 2024: $2,340 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,251 · Education: $19.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,250.59 |
| Education | $19.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,876.23 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,583.77 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,429.04 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $883.30 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $860.61 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $828.11 | 2021-2025 | Rexulti, Nuedexta |
| Corium, LLC | $775.21 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $729.94 | 2021-2025 | Caplyta |
| Lundbeck LLC | $524.13 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $480.97 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $435.25 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $314.17 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $265.24 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neos Therapeutics, LP | $178.32 | 2022-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $140.39 | 2022-2024 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $132.37 | 2022-2025 | Dyanavel Xr |
| Indivior INC. | $123.07 | 2022-2024 | Perseris |
| Almatica Pharma LLC | $82.41 | 2023-2025 | Gralise, Loreev Xr |
| Janssen Biotech, INC. | $63.28 | 2024-2025 | Tremfya, Stelara |
| Sunovion Pharmaceuticals INC. | $60.97 | 2021 | |
| Noven Therapeutics, LLC | $42.62 | 2023 | Xelstrym |
| Collegium Pharmaceutical, INC. | $19.43 | 2025 | Jornay Pm |
| Ipsen Biopharmaceuticals, INC | $17.20 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.